Handelsbanken Fonder AB Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Handelsbanken Fonder AB grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,837 shares of the medical research company’s stock after purchasing an additional 200 shares during the period. Handelsbanken Fonder AB’s holdings in Charles River Laboratories International were worth $2,089,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in CRL. VisionPoint Advisory Group LLC boosted its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth $37,000. Operose Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $42,000. Venturi Wealth Management LLC boosted its position in shares of Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after buying an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $57,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock valued at $3,693,663 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE CRL opened at $229.03 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $11.80 billion, a PE ratio of 24.87, a P/E/G ratio of 1.88 and a beta of 1.40. The firm has a fifty day moving average of $253.48 and a 200-day moving average of $222.64. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same period in the prior year, the firm posted $2.98 earnings per share. The firm’s revenue was down 7.9% on a year-over-year basis. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. UBS Group boosted their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Argus increased their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).